CellaVision AB (publ) (CLVSF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
CellaVision AB (publ) (CLVSF) with AI Score 52/100 (Hold). CellaVision AB (publ) specializes in developing and selling digital solutions for blood and body fluid analysis, primarily serving the healthcare sector. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026CellaVision AB (publ) (CLVSF) Healthcare & Pipeline Overview
CellaVision AB (publ) provides digital solutions for blood and body fluid analysis, automating and standardizing morphological examination. Serving hospitals and commercial labs globally, the company's key differentiators include its advanced cell imaging technology and comprehensive software suite, positioning it as a leader in hematology diagnostics within the medical devices sector.
Investment Thesis
CellaVision AB (publ) presents a notable research candidate within the medical devices sector, driven by the increasing demand for automated and standardized diagnostic solutions. The company's strong gross margin of 68.5% and profit margin of 20.2% indicate efficient operations and pricing power. Growth catalysts include the expansion of its product portfolio and penetration into new geographic markets. Key value drivers include the recurring revenue from software licenses and service contracts, as well as the potential for increased adoption of its solutions in veterinary medicine. Potential risks include competition from established players and the impact of regulatory changes on the medical devices industry. The company's P/E ratio of 23.09 suggests a premium valuation, reflecting investor expectations for future growth.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $0.38B reflects CellaVision's current valuation in the medical devices market.
- P/E Ratio of 23.09 indicates the price investors are willing to pay for each dollar of CellaVision's earnings.
- Profit Margin of 20.2% demonstrates CellaVision's ability to generate profit from its revenue.
- Gross Margin of 68.5% showcases the efficiency of CellaVision's production and pricing strategies.
- Dividend Yield of 1.69% provides investors with a return on their investment through dividend payments.
Competitors & Peers
Strengths
- Proprietary technology in digital cell morphology.
- Strong brand reputation and established customer base.
- High gross and profit margins.
- Comprehensive suite of hardware and software solutions.
Weaknesses
- Limited geographic diversification.
- Dependence on hospital and commercial laboratories.
- Relatively small market capitalization.
- OTC market listing may limit investor access.
Catalysts
- Ongoing: Expansion into emerging markets, driven by increasing healthcare investments in Asia Pacific and Latin America.
- Ongoing: Product portfolio diversification with new applications for hematology and diagnostics.
- Upcoming: Potential strategic partnerships or acquisitions to expand market reach and capabilities.
- Ongoing: Increased adoption of CellaVision VET solutions in the growing veterinary medicine market.
- Ongoing: Development and integration of AI-powered diagnostic tools for improved accuracy and efficiency.
Risks
- Potential: Increased competition from established medical device companies with greater resources.
- Potential: Regulatory changes in the healthcare industry affecting product approvals and reimbursement.
- Potential: Economic downturns impacting hospital budgets and capital expenditures.
- Potential: Technological obsolescence requiring continuous innovation and product development.
- Ongoing: Risks associated with OTC market listing, including limited liquidity and disclosure.
Growth Opportunities
- Expansion into Emerging Markets: CellaVision has the opportunity to expand its presence in emerging markets, such as Asia Pacific and Latin America, where healthcare infrastructure is rapidly developing and the demand for advanced diagnostic solutions is increasing. These markets offer significant growth potential due to their large populations and unmet medical needs. Successful penetration into these regions could substantially increase CellaVision's revenue and market share over the next 3-5 years.
- Product Portfolio Diversification: CellaVision can diversify its product portfolio by developing new applications and solutions for different areas of hematology and diagnostics. This could include expanding into molecular diagnostics or developing specialized solutions for specific diseases. By broadening its product offerings, CellaVision can attract new customers and increase its revenue per customer, driving long-term growth.
- Strategic Partnerships and Acquisitions: CellaVision can pursue strategic partnerships and acquisitions to expand its capabilities and market reach. Collaborating with other companies in the medical devices or diagnostics industry can provide access to new technologies, markets, and customers. Acquisitions can also be used to consolidate the market and eliminate competition, creating a stronger and more dominant player.
- Increased Adoption in Veterinary Medicine: CellaVision's VET solution offers a significant growth opportunity in the veterinary medicine market. As pet ownership continues to rise and veterinary practices become more sophisticated, the demand for advanced diagnostic solutions in veterinary care is increasing. By focusing on this market, CellaVision can leverage its existing technology and expertise to capture a growing share of the veterinary diagnostics market.
- Development of AI-Powered Diagnostic Tools: CellaVision can leverage artificial intelligence (AI) to develop new diagnostic tools that improve the accuracy and efficiency of cell morphology analysis. AI-powered solutions can automate the identification and classification of cells, reducing the workload for laboratory technicians and improving diagnostic accuracy. This can lead to increased adoption of CellaVision's solutions and a competitive advantage in the market.
Opportunities
- Expansion into emerging markets.
- Product portfolio diversification.
- Increased adoption in veterinary medicine.
- Development of AI-powered diagnostic tools.
Threats
- Competition from established medical device companies.
- Regulatory changes in the healthcare industry.
- Economic downturns affecting hospital budgets.
- Technological obsolescence.
Competitive Advantages
- Proprietary technology in digital cell morphology analysis.
- Established customer base in hospitals and commercial laboratories.
- Integrated hardware and software solutions.
- Strong brand reputation for accuracy and reliability.
About CLVSF
CellaVision AB (publ), founded in 1994 and headquartered in Lund, Sweden, develops and markets digital solutions for blood and body fluid analysis. The company's core products include the CellaVision DM1200, DM9600, and DC-1 analyzers, which automatically capture digital images of cells from blood smears and body fluid preparations. These analyzers are complemented by a suite of software applications, such as the CellaVision Peripheral Blood Application, Advanced RBC Application, Body Fluid Application, and Remote Review Software, designed to automate, standardize, and simplify morphological examination. CellaVision's solutions cater to hospital and commercial laboratories, enabling them to streamline workflows, improve accuracy, and enhance efficiency in hematology diagnostics. The company's geographic reach extends across Europe, the Middle East, Africa, the Americas, and the Asia Pacific. CellaVision differentiates itself through its integrated hardware and software approach, offering a comprehensive solution for digital cell morphology. This positions them competitively against other players in the medical devices market, particularly those focused on laboratory automation and diagnostics.
What They Do
- Develops and sells digital imaging solutions for blood and body fluid analysis.
- Offers automated cell morphology analyzers for hospital and commercial laboratories.
- Provides software applications for streamlining and standardizing diagnostic workflows.
- Enables remote review of blood smears and body fluid preparations.
- Offers solutions for both human and veterinary hematology.
- Provides tools for assessing and monitoring staff competency in cell morphology.
Business Model
- Sells automated cell morphology analyzers (CellaVision DM1200, DM9600, DC-1) to hospitals and commercial labs.
- Generates recurring revenue through software licenses and service contracts.
- Offers cloud-based software solutions for proficiency testing and education.
- Provides digital solutions for medical microscopy in veterinary hematology.
Industry Context
CellaVision AB (publ) operates within the medical devices industry, specifically focusing on in-vitro diagnostics and laboratory automation. The industry is characterized by technological advancements, increasing regulatory scrutiny, and growing demand for accurate and efficient diagnostic solutions. The global in-vitro diagnostics market is projected to reach $100 billion by 2028, driven by the rising prevalence of chronic diseases and the increasing adoption of point-of-care testing. CellaVision competes with other medical device manufacturers and diagnostic companies, including AVNBF (Avon Rubber P.L.C.) and BJTRF (Bio-Rad Laboratories, Inc.), in a fragmented market landscape.
Key Customers
- Hospital laboratories
- Commercial laboratories
- Veterinary clinics and hospitals
- Research institutions
Financials
Chart & Info
CellaVision AB (publ) (CLVSF) stock price: Price data unavailable
Latest News
-
3 Undervalued European Small Caps With Insider Buying
Simply Wall St. · Feb 16, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CLVSF.
Price Targets
Wall Street price target analysis for CLVSF.
MoonshotScore
What does this score mean?
The MoonshotScore rates CLVSF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Simon Ostergaard
CEO
Simon Ostergaard serves as the CEO of CellaVision AB (publ). Information regarding his detailed career history and educational background is not available in the provided data. As CEO, he is responsible for leading the company's strategic direction, overseeing operations, and driving growth in the global market for digital cell morphology solutions. His leadership is crucial for CellaVision's continued success and innovation in the healthcare sector.
Track Record: Specific achievements and milestones under Simon Ostergaard's leadership are not detailed in the provided data. However, as CEO, he is responsible for overseeing the company's financial performance, product development, and market expansion. His strategic decisions and leadership play a critical role in shaping CellaVision's future growth and competitive positioning.
CLVSF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that CellaVision AB (publ) may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting and regulatory oversight compared to those listed on major exchanges like the NYSE or NASDAQ. This can result in higher risks for investors due to the potential for less transparency and greater information asymmetry.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and regulatory oversight.
- Lower trading volume and liquidity.
- Wider bid-ask spreads.
- Potential for price manipulation and fraud.
- Higher information asymmetry.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's growth prospects and potential risks.
- Monitor trading volume and price volatility.
- Consult with a financial advisor before investing.
- Understand the risks associated with OTC investing.
- Established business operations in the healthcare sector.
- Proprietary technology in digital cell morphology analysis.
- Customer base of hospitals and commercial laboratories.
- Presence in multiple geographic markets (Europe, Americas, Asia Pacific).
- Positive gross and profit margins.
CLVSF Healthcare Stock FAQ
What does CellaVision AB (publ) do?
CellaVision AB (publ) develops, markets, and sells digital solutions for blood and body fluid analysis within the healthcare sector. Their core offering includes automated cell morphology analyzers, such as the DM1200 and DM9600, which capture digital images of cells from blood smears. These analyzers, coupled with specialized software applications, enable laboratories to automate, standardize, and simplify the morphological examination process, improving efficiency and accuracy in hematology diagnostics for hospitals and commercial labs globally.
What do analysts say about CLVSF stock?
AI analysis is pending for CLVSF, therefore current analyst ratings and price targets are unavailable. Investors should monitor for future updates regarding analyst coverage. Key valuation metrics to consider include the company's P/E ratio of 23.09, gross margin of 68.5%, and profit margin of 20.2%. Growth considerations include the company's expansion into emerging markets, product portfolio diversification, and potential for increased adoption in veterinary medicine. The OTC market listing and associated risks should also be carefully evaluated.
What are the main risks for CLVSF?
The main risks for CellaVision AB (publ) include competition from larger, more established medical device companies, potential regulatory changes affecting product approvals and reimbursement, and economic downturns impacting hospital budgets. Additionally, the company faces the risk of technological obsolescence, requiring continuous innovation and product development. As an OTC-listed stock, CLVSF also carries risks associated with limited liquidity, disclosure, and regulatory oversight, potentially leading to increased price volatility and information asymmetry for investors.
What are the key factors to evaluate for CLVSF?
CellaVision AB (publ) (CLVSF) currently holds an AI score of 52/100, indicating moderate score. Key strength: Proprietary technology in digital cell morphology.. Primary risk to monitor: Potential: Increased competition from established medical device companies with greater resources.. This is not financial advice.
How frequently does CLVSF data refresh on this page?
CLVSF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CLVSF's recent stock price performance?
Recent price movement in CellaVision AB (publ) (CLVSF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary technology in digital cell morphology.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CLVSF overvalued or undervalued right now?
Determining whether CellaVision AB (publ) (CLVSF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CLVSF?
Before investing in CellaVision AB (publ) (CLVSF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- AI analysis is pending and may provide further insights.